Bide Pharmatech (SH:688073) KAIYUAN SECURITIES·2026-03-01 13:43Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company is expected to achieve a revenue of 1.324 billion yuan in 2025, representing a year-on-year growth of 20.13%, and a net profit of 152 million yuan, which is an increase of 29.61% [4] - The company has a strong product matrix and competitive advantage in its offerings, which is expected to enhance its profitability [5][6] - The company has adjusted its profit forecasts for 2025-2027, with expected net profits of 152 million, 227 million, and 284 million yuan respectively, leading to an EPS of 1.68, 2.50, and 3.13 yuan per share [4] Financial Performance Summary - The company reported a revenue of 1.324 billion yuan for 2025, with a year-on-year growth of 20.1% [7] - The net profit for 2025 is projected at 152 million yuan, reflecting a growth of 29.7% [7] - The gross margin is expected to improve to 44.3% in 2025, with a net margin of 11.5% [7] - The company’s P/E ratio is projected to decrease from 34.8 in 2025 to 18.6 in 2027, indicating a more attractive valuation over time [7] Product and R&D Insights - The company has developed a vast product library with nearly one million molecular building blocks and scientific reagents, with over 140,000 types of products available [5] - Continuous investment in R&D is evident, with R&D expenses amounting to 46 million yuan in the first three quarters of 2025, representing 4.70% of revenue [6] - The company is focusing on high-value, customized molecular building blocks to meet the evolving needs of clients in drug development [6]